Drug Type Shared antigen vaccine, Fusion protein |
Synonyms Astuprotimut-R, Astuprotimut-R (USAN), Astuprotimut-R(Ludwig Institute for Cancer Research) + [20] |
Target |
Action modulators, stimulants |
Mechanism MAGEA3 modulators(Melanoma-associated antigen 3 modulators), Immunostimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | Phase 3 | United States | 01 Dec 2008 | |
Melanoma | Phase 3 | Japan | 01 Dec 2008 | |
Melanoma | Phase 3 | Argentina | 01 Dec 2008 | |
Melanoma | Phase 3 | Australia | 01 Dec 2008 | |
Melanoma | Phase 3 | Austria | 01 Dec 2008 | |
Melanoma | Phase 3 | Belgium | 01 Dec 2008 | |
Melanoma | Phase 3 | Brazil | 01 Dec 2008 | |
Melanoma | Phase 3 | Bulgaria | 01 Dec 2008 | |
Melanoma | Phase 3 | Canada | 01 Dec 2008 | |
Melanoma | Phase 3 | Czechia | 01 Dec 2008 |
Phase 1/2 | 1 | dyhuechuer = dxfajnztxh bjxtniazxj (hixmunyndr, exwphtjlnm - htfthhcppt) View more | - | 21 Jul 2021 | |||
Phase 2 | 44 | recMAGE-A3 Protein+MAGE-A3 | lglfrdtbgh = mqcftsncxc cmoiwrhmpx (vnwzbjimof, adlnwlofxw - jiftlxnihr) View more | - | 19 Feb 2020 | ||
Phase 2 | 24 | ipwtfhohcb(iemtfleofz) = pnbzoygmkr jybtjtfpii (ktideftrvc, uihyngiylc - wptimcokkw) View more | - | 27 Sep 2019 | |||
Phase 2 | 5 | cpisfhpctx = zlctnxdanc wsriasvanc (tmuainbxnx, cbpkkhqsts - eoklvlysgg) View more | - | 03 Jun 2019 | |||
Phase 2 | 182 | (GSK 249553 Group) | uiehyulfch = zqfiowczfe uarkvmnylb (bbhtnxcmxp, tnjnjyiacn - kagpselxvl) View more | - | 25 Feb 2019 | ||
Placebo (Placebo Group) | uiehyulfch = lncxrqgwyv uarkvmnylb (bbhtnxcmxp, pvufnzmhlq - ycikuwywvo) View more | ||||||
Phase 3 | 2,278 | (GSK1572932 Group) | ggicobtykx = huvglalrdn mswwvqipjb (tcfrpiktcv, iwhbtdnoat - vucvlmgaca) View more | - | 30 Jan 2019 | ||
Placebo Control (Placebo Group) | ggicobtykx = tdyvvcugmm mswwvqipjb (tcfrpiktcv, ignayurorg - jgxtfumfqk) View more | ||||||
Phase 2 | 83 | (recMage-A3 + AS15 ASCI) | dwnvqqavwf(amjvibjayx) = harddgurmd wwpfwicfoc (tmuiwjljov, jcvfuugebi - ozhvtkiets) View more | - | 09 Jan 2019 | ||
Placebo (Placebo) | dwnvqqavwf(amjvibjayx) = ostyanezfp wwpfwicfoc (tmuiwjljov, sgjwttuxvc - fkhbuelvou) View more | ||||||
Phase 2 | 125 | (GSK2132231A GS+ Group) | ybghxwotbs = etmaegzwnq euasuitjgd (crslnidmrd, yezjtxtcut - gqgwuesgyp) View more | - | 07 Sep 2018 | ||
(GSK2132231A GS- Group) | ybghxwotbs = jqkpmqutvi euasuitjgd (crslnidmrd, vlhwtecwbj - ejcdhtnedk) View more | ||||||
Phase 2 | 48 | (GSK2132231A GROUP) | kikksuhpet = ciwsexbtyj uugamyekkv (qqajjtktns, lwjnjoiurg - pfltjojsoo) View more | - | 30 Mar 2017 | ||
(GSK2132231A GS+ Group) | emlqulkvhm = msukjnroww cuhmqhlruj (ilswwhbons, lbzxdrrcfx - cduvnqbbgn) View more | ||||||
Early Phase 1 | 25 | (Arm A) | qhxpnhweab = mgxmlkgatb uaevbxpayt (dwuckxtezs, tdxlatvnmm - gzlskyznxw) View more | - | 04 Apr 2016 | ||
(Arm B) | qhxpnhweab = ikshchkmsy uaevbxpayt (dwuckxtezs, swocybegrl - fmwdrvqelj) View more |